Advanced search
Publication Cover
Future Virology Volume 2, 2007 - Issue 1
Submit an article Journal homepage
118
Views
0
CrossRef citations to date
0
Altmetric
Review

Future Therapy for Hepatitis B

Vinod K RustgiCorrespondence[email protected]
&
Raymond S KoffUniversity of Connecticut,School of Medicine,Farmington,Connecticut,USA Tel.: +1 617 232 4298; Fax.: +1 617 232 0896;[email protected]
Pages 79-90 | Published online: 20 Dec 2006

Bibliography

  • Lee W : Hepatitis B virus infection.N. Engl. J. Med.337, 1733–1745 (1997).
  • McMahon BJ , AlwardWLM, HallDBet al.: Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state.J. Infect. Dis.151, 599–603 (1985).
  • Tassopoulos NC , PapaevangelouGJ, SjogrenMHet al.: Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults.Gastroenterology92, 1844–1850 (1987).
  • Grob PJ : Hepatitis B: virus, pathogenesis and treatment.Vaccine16, S11–S16 (1998).
  • Rehermann B , NascimbeniM: Immunology of hepatitis B and C virus infection.Nat. Rev. Immunol.5(3), 215–229 (2005).
  • Beasley RP : Hepatitis B virus: the major etiology of hepatocellular carcinoma.Cancer61, 1942–1956 (1988).
  • Kim WR , VeenstraD, IloejeUHet al.: The natural history of chronic hepatitis B infection: a new computer simulation model to incorporate events subsequent to HBeAg seroconversion.Gastroenterology128(4 Suppl. 1), A692 (2005).
  • Chang M-H , ChenC-J, LaiM-Set al.: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children.N. Engl. J. Med.336, 1855–1859 (1997).
  • Lin HH , WangLY, HuCTet al.: Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan.J. Med. Virol.69, 471–474 (2003).
  • Namgyal P : Impact of hepatitis B immunization in Europe and worldwide. Presented at: European Association for the Study of the Liver. Consensus Conference on Hepatitis B.Geneva, Switzerland, 12–14September (2002).
  • McQuillan GM , ColemanPJ, Kruszon–MoranDet al.: Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994.Am. J. Public Health89, 14–18 (1999).
  • Poland GA , JacobsonRM: Prevention of hepatitis B with the hepatitis B vaccine.N. Engl. J. Med.351(27), 2832–2838 (2004).
  • Meuleman P , LibbrechtL, WielandSet al.: Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus.J. Virol.80(6), 2797–2807 (2006).
  • Chen CJ , YangHI, SuJet al.: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.JAMA295(1), 65–73 (2006).
  • Iloeje UH , YangH-I, SuJet al.: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.Gastroenterology130(3), 678–686 (2006).
  • Mommeja-Marin H , MondouE, BlumMR, RousseauF. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection (analysis and review of the literature).Hepatology37, 1309–1319 (2003).
  • Hu Z , ZhangZ, KimJWet al.: Altered proteolysis and global gene expression in hepatitis B virus X transgenic mouse liver.J. Virol.80(3), 1405–1413 (2006).
  • Sung JJ Wong ML , BowdenSet al.: Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy.Gastroenterology128(7), 1890–1897 (2005).
  • Werle-Lapostolle B , BowdenS, LocarniniSet al.: Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.Gastroenterology126(7), 1750–1758 (2004).
  • Perlman DH , BergEA, O‘ConnorPBet al.: Reverse transcription-associated dephosphorylation of hepdnavirus nucleocapsids.Proc. Natl Acad. Sci. USA102(25), 9020–9025 (2005).
  • Schormann W , KraftA, PonselD, BrussV: Hepatitis B virus particle formation in the absence of pregenomic RNA and reverse transcriptase.J. Virol.80(8), 4187–4190 (2006).
  • Wieland SF , EustaquioA, Whiten-BauerC, BoydB, ChisariFV: Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids.Proc. Natl Acad. Sci. USA102(28), 9913–9917 (2005).
  • Janssen HLA , von ZannoveldM, SenturkHet al.: Pegylated interferon-α2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.Lancet351, 123–129 (2005).
  • Lau GKK , PiratvisuthT, LuoKXet al.: Peginterferon-α2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.N. Engl. J. Med.352, 2682–2695 (2005).
  • Marcellin P , LauGKK, BoninoFet al.: Peginterferon-α2a alone, lamivudine alone, and two in combination in patients with HBeAg-negative chronic hepatitis B.N. Engl. J. Med.351, 12060–12170 (2004).
  • Arase Y , IkedaK, SuzukiFet al.: Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitisB. Am. J. Med.119(71), E9–E16 (2006).
  • Robek MD , BoydBS, ChisariFV: λ interferon inhibits hepatitis B and C virus replication.J. Virol.79(6), 3851–3854 (2005).
  • Hui CK , LauGK: Clevudine for the treatment of chronic hepatitis B virus infection.Expert Opin. Investig. Drugs14(10), 1277–1284 (2005).
  • Chang TT , GishRG, deManRet al.: A comparison of entecavir to lamivudine for HBeAg-positive chronic hepatitis B.N. Engl. J. Med.354, 1–10 (2006).
  • Lai CL , GaneE, LiawY-Fet al.: Telbivudine (LDT) versus lamivudine for chronic hepatitis B: first-year results from the international Phase III Globe trial.Hepatology42(Suppl. 1), A748 (2006).
  • Marcellin P , ChangTT, LimSGet al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.N. Engl. J. Med.348(9), 808–816 (2003).
  • Lai CL , ShouvalD, LokASet al.: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.N. Engl. J. Med.354, 11–20 (2006).
  • Hadziyannis SJ , TassopoluosNC, HeathcoteEJet al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.N. Engl. J. Med.348(9), 800–807 (2003).
  • Lai CL , LeungN, TeoEKet al.: A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.Gastroenterology129, 528–536 (2005).
  • Liu C-J , LaiM-Y, ChaoY-Cet al.: Interferon-α2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study.Hepatology43, 742–749 (2006).
  • Yang H , QiX, SabogalAet al.: Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV.Antivir. Ther.10(5), 625–633 (2005).
  • Yang J , BoXC, DingXRet al.: Antisense oligonucleotides targeted against asialoglycoprotein receptor 1 block human hepatitis B virus replication.J. Viral Hepat.13(3), 158–165 (2006).
  • Owada T , MatsubayashiK, SakataHet al.: Interaction between desialyated hepatitis B virus and asialoglycoprotein receptor on hepatocytes may be indispensable for viral binding and entry.J. Viral Hepat.13(1), 11–18 (2006).
  • Gripon P , CannieI, UrbanS: Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein.J. Virol.79(3), 1613–1622 (2005).
  • Barrera A , GuerraB, NotvallL, LanfordRE: Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition.J. Virol.79(15), 9786–9798 (2005).
  • Engelke M , MillsK, SeitzSet al.: Characterization of a hepatitis B and hepatitis D virus receptor binding site.Hepatology43(4), 750–760 (2006).
  • Li Y , FuL, YeoHet al.: Inhibition of hepatitis B virus gene expression and replication by helioxanthin and its derivative.Antivir. Chem. Chemother.16(3), 193–201 (2005).
  • Cheng Y-C , YingC-X, LeungC-H, LiY: New targets and inhibitors of HBV replication to combat drug resistance.J. Clin. Virol.34(Suppl. 1), S147–S150 (2005).
  • Melegari M , WolfSK, SchneiderRJ: Hepatitis B virus DNA replication is coordinated by core protein serine phosphorylation and HBx expression.J. Virol.79(15), 9810–9820 (2005).
  • Kann M : Interfering with capsid formation: a practicable antiviral strategy against hepatitis B virus?Hepatology39(3), 838–840 (2004).
  • Butz K , DenkC, FitscherBet al.: Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity.Oncogene20(45), 6579–6586 (2001).
  • Deres K , SchroderCH, PaessensAet al.: Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids.Science299, 893–896 (2003).
  • Stray SJ , BourneCR, PunnaSet al.: A heteroaryldihydropyrimidine activates and misdirects hepatitis B capsid assembly.Proc. Natl Acad. Sci. USA102(23), 8138–8143 (2005).
  • Semaine W , JoharM, TyrrellDLet al.: Inhibition of hepatitis B virus (HBV) replication by pyrimidines bearing an acyclic moiety: effect on wild-type and mutant HBV.J. Med. Chem.49(6), 2049–2054 (2006).
  • Stray SJ , JohnsonJM, KopekBG, ZlotnickA: An in vitro fluorescence screen to identify antiviral that disrupt hepatitis B virus capsid assembly.Nat. Biotechnol.24(3), 358–362 (2006).
  • Delaney WE , EdwardsR, ColledgeDet al.: Phenypropenamide derivatives A-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro.Antimicrob. Agents Chemother.46(9), 3057–3060 (2002).
  • Lin W-J , LiJ, LeeY-Fet al.: Suppression of hepatitis B core promoter by the nuclear orphan receptor TR4.J. Biol. Chem.278(11), 9353–9360 (2003).
  • Simsek E , MehtaA, ZhouTet al.: Hepatitis B large and middle glycoproteins are degraded by a proteasome pathway in glucosidase-inhibited cells but not in cells with functional glucosidase enzyme.J. Virol.79(20), 12914–12920 (2005).
  • Lu X , TranT, SimsekE, BlockTM: The alkylated imino sugar, n-(n-Nonyl)-deoxygalactonojirimycin, reduces the amount of hepatitis B virus nucleocapsid in tissue culture.J. Virol.77(22), 11933–11940 (2003).
  • McCaffrey AP , NakaiH, PandeyKet al.: Inhibition of hepatitis B virus in mice by RNA interference.Nat. Biotechnol.21, 639–644 (2003).
  • Morrissey DV , LeePA, JohnsonDAet al.: Characterization of nuclease-resistant ribozymes directed against hepatitis B virus RNA.J. Viral Hepatitis9, 411–418 (2002).
  • Shlomai A , ShaulY. Inhibition of hepatitis B virus expression and replication by RNA interference.Hepatology37, 764–770 (2003).
  • Wu H-L , HuangL-R, HuangCCet al.: RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant.Gastroenterology128(3), 708–716 (2005).
  • Nash KL , AlexanderGJ, LeverAM: Inhibition of hepatitis B virus by lentiviral vector delivered antisense RNA and hammerhead ribozymes.J. Viral Hepat.12(4), 346–356 (2005).
  • Li X , KuangE, DaiWet al.: Efficient inhibition of hepatitis B virus replication by hammerhead ribozymes delivered by hepatitis δ virus.Virus Res.114(1–2), 126–132 (2005).
  • Ng LF , ChanM, ChanSHet al.: Host heterogeneous ribonucleoprotein K (hnRNP K) as a potential target to suppres hepatitis B virus replication.PLoS Med.2, e163 (2005).
  • Yang J , DingX, ZhangYet al.: Fibronectin is essential for hepatitis B virus infection and replication:may be a potential drug target?Biochem. Biophys. Res. Commun.344(3), 757–764 (2006).
  • Park SG , LeeSM, JungG: Antisense oligodeoxynucleotides targeted against molecular chaperonin Hsp60 block human hepatitis B virus replication.J. Biol. Chem.278(4), 39851–39857 (2003).
  • Kimura K , KakimiK, WielandSet al.: Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice.J. Virol.76(21), 10702–10707 (2002).
  • Rigopoulou EI , SuriD, ChokshiSet al.: Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity.Hepatology42(5), 1028–1036 (2005).
  • Isogawa M , RobekMD, FuruichiY, ChisariFV: Toll-like receptor signaling inhibits hepatitis B virus replication in vivo.J. Virol.79(11), 7269–7272 (2005).
  • Fazle Akbar SM , FurukawaS, OnjiMet al.: Safety and efficacy of hepatitis B surface antigen-pulsed dendritic cells in human volunteers.Hepatol. Res.29(3), 136–141 (2004).
  • Chen M , LiY-G, ZhangD-Zet al.: Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study.World J. Gastroenterol.11(12), 1806–1808 (2005).
  • Rustgi VK : Thymalfasin for the treatment of chronic hepatitis C infection.Expert Rev. Anti-Infective Ther.3(6), 885–892 (2005).
  • Chien RN , LiawYF. Thymalfasin for the treatment of chronic hepatitis B.Expert Rev. Anti-Infective Ther.2(1), 9–16 (2004).
  • Iino S , ToyotaJ, KumadaHet al.: The efficacy and safety of thymosin α-1 in Japanese patients with chronic hepatitis B: results from a randomized clinical trial.J. Viral Hepat.12(3), 300–306 (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.